Australia markets closed

Xenon Pharmaceuticals Inc. (XENE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
35.24+1.12 (+3.28%)
At close: 04:00PM EST
35.28 +0.04 (+0.11%)
After hours: 07:37PM EST
Full screen
Trade prices are not sourced from all markets
Previous close34.12
Bid0.00 x 900
Ask56.03 x 900
Day's range33.63 - 35.75
52-week range27.99 - 43.75
Avg. volume534,447
Market cap2.306B
Beta (5Y monthly)1.31
PE ratio (TTM)N/A
EPS (TTM)-2.66
Earnings date28 Feb 2024 - 04 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est52.04
  • Zacks

    Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study

    Xenon (XENE) posts top-line data from a phase II proof-of-concept study evaluating its pipeline candidate, XEN1101, for treating moderate-to-severe major depressive disorder. Stock rises.

  • Reuters

    UPDATE 1-Canada's Xenon Pharma's depression drug fails to meet main goal in study

    Canada's Xenon Pharmaceuticals said on Monday that its experimental drug to treat moderate to severe major depressive disorder (MDD) had failed to significantly reduce the severity of depressive episodes compared to a placebo, in a mid-stage study. Still, the company said it was actively exploring future development of the drug candidate, XEN1101, as a treatment for MDD. Xenon said the study data was compelling, building upon the ongoing late-stage study for the use of XEN1101 in treating epilepsy.

  • GlobeNewswire

    Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)

    Conference call today at 8:30 am ETVANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported topline results from the randomized, double-blind, placebo-controlled, Phase 2 proof-of-concept X-NOVA clinical trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of XEN1101 in 168 patients with moderate to severe major depressive disorder, or MDD. Summary of